(Datopotamab)Biosimilar Reference Antibody-GS40169主打

货号：GS40169

Datopotamab deruxtecan (also known as Dato-DXd or DS-1062) is an investigational antibody-drug conjugate (ADC) developed for the treatment of advanced solid tumors, most notably non-small cell lung cancer (NSCLC) and triple-negative breast cancer (TNBC). It is composed of a humanized monoclonal antibody directed against TROP2, a linker, and a potent topoisomerase I inhibitor payload. Clinical trials have demonstrated promising efficacy in patients with heavily pretreated disease, leading to its Breakthrough Therapy Designation in the U.S. for certain NSCLC and breast cancer indications.